Takeda Reportedly Considers Sale Of $3 Billion In Emerging-Market Assets

(RTTNews) - Takeda Pharmaceutical Co. (TKPYY.PK) is considering a sale of some emerging-market drugs, as the Japanese drugmaker expands a push to cut debt after its $62 billion takeover of Shire Plc, Bloomberg reported citing people familiar with the matter.

The company is working with Bank of America Corp. to gauge potential buyer interest in emerging-market assets it acquired through its 2011 purchase of Swiss rival Nycomed, according to the people. The medicines, which include over-the-counter and prescription drugs, could fetch about $3 billion, the report said.

"No decisions have been made regarding specific assets for potential disposal at this stage," a spokeswoman for Takeda reportedly said.